### Pharmacology of Recent Oncology Oral, Biologic and Immunotherapy Agents

<div class="crname">Chad Ricard BSc Pharm Aug 2021</div>

---
### Learning Objectives
- To be able to descibe the mechanisms of action and basic kinetics of commonly used newer oral, biologic and immunologic anticancer agents.
- To review how various pharmacologic strategies are used in the treatmen of specific tumor types
- To be able to discuss some challenges with use of these agents

---

#### Preamble

Efforts have been made to ensure the accuracy of the information contained within this document, however, are meant to be for educational purposes only. Linkages to the relevant monographs have been made and should be referred to for information related to treatment of patients. The author accepts no liability for any errors or omissions contained within. Information is provided as is and is not a replacement for clinical judgment of a licenced medical practitioner.

An online version of this presentation is hosted at <a href="https://cricard7.github.io/chemoPharmacology/">this link </a>

---

<div id="TOC" class="scrollable">

<div ></div>

#### Table of Contents (Scrollable)
<table class="datatbl">
<tbody>
<tr>
<td><a href="#/Abemaciclib">Abemaciclib</a></td>
<td><a href="#/Abemaciclib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Abiraterone">Abiraterone</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059559.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Acalabrutinib">Acalabrutinib</a></td>
<td><a href="#/Acalabrutinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Afatinib">Afatinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00051644.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Alectinib">Alectinib</a></td>
<td><a href="#/Alectinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Alpelisib">Alpelisib</a></td>
<td><a href="#/Alpelisib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Anastrazole">Anastrazole</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062049.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Apalutamide">Apalutamide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062050.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Arsenic Trioxide">Arsenic Trioxide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058402.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Atezolizumab">Atezolizumab</a></td>
<td><a href="#/Atezolizumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Avelumab">Avelumab</a></td>
<td><a href="#/Avelumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Axitinib">Axitinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054598.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Bevacizumab">Bevacizumab</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059621.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Bicalutamide">Bicalutamide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040132.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Blinatumomab">Blinatumomab</a></td>
<td><a href="#/Blinatumomab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Bosutinib">Bosutinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052636.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Brentuximab vedotin">Brentuximab vedotin</a></td>
<td><a href="#/Brentuximab vedotin">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Brigatinib">Brigatinib</a></td>
<td><a href="#/Brigatinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Cabozantinib">Cabozantinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056366.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Capecitabine">Capecitabine</a></td>
<td><a href="#/Capecitabine">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Cemiplimab">Cemiplimab</a></td>
<td><a href="#/Cemiplimab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Ceritinib">Ceritinib</a></td>
<td><a href="#/Ceritinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Cetuximab">Cetuximab</a></td>
<td><a href="#/Cetuximab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Chorambucil">Chorambucil</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052423.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Cobimetinib">Cobimetinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043025.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Crizotinib">Crizotinib</a></td>
<td><a href="#/Crizotinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Cyclophosphamide">Cyclophosphamide</a></td>
<td><a href="#/Cyclophosphamide">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Dabrafenib">Dabrafenib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060490.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Dacometinib">Dacometinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050253.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Daratumumab">Daratumumab</a></td>
<td><a href="#/Daratumumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Darolutamide">Darolutamide</a></td>
<td><a href="#/Darolutamide">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Dasatinib">Dasatinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057843.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Dexamethasone">Dexamethasone</a></td>
<td>
<a href="#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Dinutuximab">Dinutuximab</a></td>
<td><a href="#/Dinutuximab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Durvalumab">Durvalumab</a></td>
<td><a href="#/Durvalumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Entrectinib">Entrectinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059544.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Enzalutamide">Enzalutamide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057056.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Erlotinib">Erlotinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047154.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Etoposide">Etoposide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054405.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Everolimus">Everolimus</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060902.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Exemestane">Exemestane</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044156.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Flutamide">Flutamide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050081.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Gefitinib">Gefitinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060650.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Gemtuzumab Ozogamicin">Gemtuzumab Ozogamicin</a></td>
<td><a href="#/Gemtuzumab Ozogamicin">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Gilteritinib">Gilteritinib</a></td>
<td><a href="#/Gilteritinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Hydroxyurea">Hydroxyurea</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054980.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Ibrutinib">Ibrutinib</a></td>
<td><a href="#/Ibrutinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Idelalisib">Idelalisib</a></td>
<td><a href="#/Idelalisib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Imatinib">Imatinib</a></td>
<td><a href="#/Imatinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Inotuzumab Ozogamicin">Inotuzumab Ozogamicin</a></td>
<td><a href="#/Inotuzumab Ozogamicin">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Ipilimumab">Ipilimumab</a></td>
<td><a href="#/Ipilimumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Isatuximab">Isatuximab</a></td>
<td><a href="#/Isatuximab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Lacrotrectinib">Lacrotrectinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060963.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Lapatinib">Lapatinib</a></td>
<td><a href="#/Lapatinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Lenalidomide">Lenalidomide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052749.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Lenvatinib">Lenvatinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059280.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Letrozole">Letrozole</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040278.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Lomustine">Lomustine</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00033792.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Lorlatinib">Lorlatinib</a></td>
<td><a href="#/Lorlatinib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Melphalan">Melphalan</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050468.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Mercaptopurine">Mercaptopurine</a></td>
<td><a href="#/Mercaptopurine">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Midostaurin">Midostaurin</a></td>
<td><a href="#/Midostaurin">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Mitotane">Mitotane</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055613.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Nilotinib">Nilotinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058886.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Nilutamide">Nilutamide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055916.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Niraparib">Niraparib</a></td>
<td><a href="#/Niraparib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Nivolumab">Nivolumab</a></td>
<td><a href="#/Nivolumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Obintutuzumab">Obintutuzumab</a></td>
<td><a href="#/Obintutuzumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Olaparib">Olaparib</a></td>
<td><a href="#/Olaparib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Osimertinib">Osimertinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059644.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Palbociclib">Palbociclib</a></td>
<td><a href="#/Palbociclib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Panitumumab">Panitumumab</a></td>
<td><a href="#/Panitumumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Pazopanib">Pazopanib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055255.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Pembrolizumab">Pembrolizumab</a></td>
<td><a href="#/Pembrolizumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Pertuzumab">Pertuzumab</a></td>
<td><a href="#/Pertuzumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Polatuzumab vedotin">Polatuzumab vedotin</a></td>
<td><a href="#/Polatuzumab vedotin">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Pomalidomide">Pomalidomide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059857.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Ponatininb">Ponatininb</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052729.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Pralatrexate">Pralatrexate</a></td>
<td><a href="#/Pralatrexate">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Prednisone">Prednisone</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00030893.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Procarbazine">Procarbazine</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040636.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Ramucirumab">Ramucirumab</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060742.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Regorafenib">Regorafenib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055344.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Ribociclib">Ribociclib</a></td>
<td><a href="#/Ribociclib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Rituximab">Rituximab</a></td>
<td><a href="#/Rituximab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Romidepsin">Romidepsin</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052382.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Ruxolitinib">Ruxolitinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061980.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Siltuximab">Siltuximab</a></td>
<td><a href="#/Siltuximab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Sonidegib">Sonidegib</a></td>
<td><a href="#/Sonidegib">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Sorafenib">Sorafenib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055343.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Sunitinib">Sunitinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052172.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Tamoxifen">Tamoxifen</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043973.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Temozolomide">Temozolomide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00039947.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Temsirolimus">Temsirolimus</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00037735.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Thalidomide">Thalidomide</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060578.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Thioguanine">Thioguanine</a></td>
<td><a href="#/Thioguanine">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Trametinib">Trametinib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060493.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Trastuzumab">Trastuzumab</a></td>
<td><a href="#/Trastuzumab">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Trifluridine-tipiracil">Trifluridine-tipiracil</a></td>
<td><a href="#/Trifluridine-tipiracil">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Vandetanib">Vandetanib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055721.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Vemurafenib">Vemurafenib</a></td>
<td>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054278.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Link Only</a></td>
</tr>
<tr>
<td><a href="#/Venetoclax">Venetoclax</a></td>
<td><a href="#/Venetoclax">Link To Slide</a></td>
</tr>
<tr>
<td><a href="#/Vismodegib">Vismodegib</a></td>
<td><a href="#/Vismodegib">Link To Slide</a></td>
</tr>
</tbody>
</table>

</div>

---

## Mechanisms of Action

---

Antibody Dependent Cellular Cytotoxicity (ADCC)
<img class="mechimg" src="https://upload.wikimedia.org/wikipedia/commons/thumb/0/05/Antibody-dependent_Cellular_Cytotoxicity.svg/2560px-Antibody-dependent_Cellular_Cytotoxicity.svg.png" alt="ADCC">

<div class="reflink">
<a href="https://en.wikipedia.org/wiki/Antibody-dependent_cellular_cytotoxicity#/media/File:Antibody-dependent_Cellular_Cytotoxicity.svg">Antibody-dependent cellular cytotoxicity</a> by <a href="https://commons.wikimedia.org/w/index.php?title=User:Satchmo2000&action=edit&redlink=1">Satchmo2000</a> licenced under <a href="https://creativecommons.org/licenses/by-sa/3.0/">CC BY-SA 3.0</a>
</div>
---

Complement Mediated Cytotoxicity 
<img class="mechimg" src="https://upload.wikimedia.org/wikipedia/commons/7/79/Rituximab_mechanisms_of_action.jpg" alt="CDC">

<div class="reflink">

[Rituximab mechanisms of action](https://upload.wikimedia.org/wikipedia/commons/7/79/Rituximab_mechanisms_of_action.jpg) by [Seyfizadeh, N., et al., A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Critical Reviews in Oncology / Hematology. 97: p. 275-290.
](https://www.sciencedirect.com/journal/critical-reviews-in-oncology-hematology) under [CC BY 2.5](https://creativecommons.org/licenses/by/2.5/deed.en)

</div>

---

Tyrosine Kinase Inhibition

"A substance that blocks the action of enzymes called tyrosine kinases. Tyrosine kinases are a part of many cell functions, including cell signaling, growth, and division. These enzymes may be too active or found at high levels in some types of cancer cells, and blocking them may help keep cancer cells from growing. Some tyrosine kinase inhibitors are used to treat cancer. They are a type of targeted therapy."

<a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tyrosine-kinase-inhibitor" target="_blank">Cancer.gov</a>

---

Check Point Inhibition

"The PD-1/PD-L1 pathway represents an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous immune anti-tumor activity. PD-L1 is overexpressed on tumor cells or on non-transformed cells in the tumor microenvironment2. PD-L1 expressed on the tumor cells binds to PD-1 receptors on the activated T cells, which leads to the inhibition of the cytotoxic T cells. These deactivated T cells remain inhibited in the tumor microenvironment."

<a href="https://www.abcam.com/cancer/cancer-immunotherapy-and-the-pd1pdl1-pathway" target="_blank">abcam.com</a>
---

EGFR inhibition

"A substance that blocks the activity of a protein called epidermal growth factor receptor (EGFR). EGFR is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide. Blocking EGFR may keep cancer cells from growing. Some EGFR inhibitors are used to treat cancer. Also called EGFR tyrosine kinase inhibitor, epidermal growth factor receptor inhibitor, and epidermal growth factor receptor tyrosine kinase inhibitor."

<a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/egfr-inhibitor" target="_blank">cancer.gov</a>
---

Fusion Protein

"A protein made from a fusion gene, which is created by joining parts of two different genes. Fusion genes may occur naturally in the body by transfer of DNA between chromosomes. For example, the BCR-ABL gene found in some types of leukemia is a fusion gene that makes the BCR-ABL fusion protein. Fusion genes and proteins can also be made in the laboratory by combining genes or parts of genes from the same or different organisms."

<a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/fusion-protein" target="_blank">cancer.gov</a>
---

Driver Mutations

"Cancer develops as a result of the accumulation of somatic mutation and other genetic alterations that impair cell division, checkpoints, etc., which results in abnormal cell proliferation and eventually tumorigenesis – such mutations are called “driver mutations” (the term driver mutation denotes mutation under positive selection within the population of cells)"

<a href="https://ijmio.com/driver-mutations-in-oncogenesis/" target="_blank">Morjaria S. Driver mutations in oncogenesis. Int J Mol Immuno Oncol 2021;6(2):100-2.</a>

---

<div id="Lorlatinib"></div>
<span class="generic">Lorlatinib</span> <span class="brand">LORBRENDA</span>

<span class="class">ALK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">3rd Gen inhibitor ALK &#x2F; ROS1.
Overcomes ALK mutations (such as post crizotinib).</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 24hr
CYP3A4
Dose adjust for renal&#x2F;hepatic dysfx</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2019-Apr </span> <span class="currentMarketDate">Current Market Date: 2019-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061480.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02485966</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97619" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Brigatinib"></div>
<span class="generic">Brigatinib</span> <span class="brand">ALUNBRIG</span>

<span class="class">ALK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor ALK, ROS1, IGF-1R, FLT-3, EGFR mutations
Activity against EML4 ALK and 17 mutant ALK (such as progression on crizotinib)</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 25 hr
CYP 2C8 and 3A4
Dose adjust in renal&#x2F;hepatic dysfx</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2018-Aug </span> <span class="currentMarketDate">Current Market Date: 2018-Aug</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060201.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02479206</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96982" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Alectinib"></div>
<span class="generic">Alectinib</span> <span class="brand">ALECENSARO</span>

<span class="class">ALK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor ALK, RET
Note more potent than crizotinib &amp; active against ALK mutations developed on crizotinib</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 33 hr
Major active metabolite M4 T1&#x2F;2: 31hr
3A4
Dose adjust Renal&#x2F;Hepatic dysfnx</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2016-Oct </span> <span class="currentMarketDate">Current Market Date: 2016-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062016.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02458136</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94518" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Ceritinib"></div>
<span class="generic">Ceritinib</span> <span class="brand">ZYKADIA</span>

<span class="class">ALK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor ALK, IGF-1, Insulin receptor, ROS1
activity in crizotinib resistant tumors</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 41hr
3A4
Dose adjust hepatic dysfnx.
Unstudied for renal</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2015-Apr </span> <span class="currentMarketDate">Current Market Date: 2015-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054572.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02436779</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92108" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Crizotinib"></div>
<span class="generic">Crizotinib</span> <span class="brand">XALKORI</span>

<span class="class">ALK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ or ROS1 positive NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor ALK, ROS1, Hepatocyte Growth Factor Receptor
Inducing apoptosis in cell lines with mutations</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 42hr
3A4&#x2F;5
Dose adjust Renal&#x2F;Hepatic dysfnx</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2012-May </span> <span class="currentMarketDate">Current Market Date: 2012-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059902.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02384256</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86999" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Blinatumomab"></div>
<span class="generic">Blinatumomab</span> <span class="brand">BLINCYTO</span>

<span class="class">Anti-CD19&#x2F;3 BiTE</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD19 B Cell &#x2F; Cd3 T Cell</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Acute Lymphocytic Leukemia PH-ve with MDR
ALL relapse
Both Pediatric and adult</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Bispecific T-Cell Engager (BITE) binds to CD 19 of B cells and CD3 of T cells creating a connection between the two.
Mediates cytolytic proteins, inflammatory cytokins and lysis of CD 19 B cells</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: Approx 2 hr
No adjustments</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2016-Mar </span> <span class="currentMarketDate">Current Market Date: 2016-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060888.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02450283</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93642" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Obintutuzumab"></div>
<span class="generic">Obintutuzumab</span> <span class="brand">GAZYVA</span>

<span class="class">Anti-CD20 Monoclonal Antibody</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD20 B Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL in combo with chemotherapy
Follicular Lymphoma in combo with chemotherapy</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Monoclonal targeting CD 20+ B lymphocytes
ADCC&#x2F;CDC, antibody depentent cellular phagocytosis
Binds more strongly than rituxan.
High risk of reactions especially with high tumor burden</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 25-35 days
No adjustments</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2014-Nov </span> <span class="currentMarketDate">Current Market Date: 2014-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059907.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02434806</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91910" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Rituximab"></div>
<span class="generic">Rituximab</span> <span class="brand">RITUXAN</span>

<span class="class">Anti-CD20 Monoclonal Antibody</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD20 B Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">NHL, CLL 
In combination with chemo or alone</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Monoclonal targeting CD 20+ B lymphocytes
ADCC&#x2F;CDC, antibody depentent cellular phagocytosis</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2 days to months
No adjustments</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2000-Mar </span> <span class="currentMarketDate">Current Market Date: 2000-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00053554.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02241927</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;65597" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Isatuximab"></div>
<span class="generic">Isatuximab</span> <span class="brand">SARCLISA</span>

<span class="class">Anti-CD38 Monoclonal Antibody</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD38 Tumor Cells</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">In combination with pom&#x2F;dex for relapse refactory myeloma</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Monoclonal targeting CD 38 expressed on hematopoeitic and tumor cells including myeloma.
ADCC&#x2F;CDC
++ risk of reactions</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">No adjustments
Contains polysorbate 80 (reactions)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Jul </span> <span class="currentMarketDate">Current Market Date: 2020-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060885.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02498235</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98801" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Daratumumab"></div>
<span class="generic">Daratumumab</span> <span class="brand">DARZALEX</span>

<span class="class">Anti-CD38 Monoclonal Antibody</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD38 Hematologic Malignancy (Myeloma)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">In combination with borez&#x2F;thalidomide&#x2F;dex,
len&#x2F;dex, bortez&#x2F;melphalan&#x2F;pred for relapse refractory myeloma</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Monoclonal targeting CD 38 expressed on hematopoeitic and tumor cells including myeloma.
ADCC&#x2F;CDC
++ risk of reactions</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18 days +&#x2F;- 9 d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2016-Jul </span> <span class="currentMarketDate">Current Market Date: 2016-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062011.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02455951</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94282" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Pralatrexate"></div>
<span class="generic">Pralatrexate</span> <span class="brand">FOLOTYN</span>

<span class="class">Antimetabolite</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Peripheral T Cell Lymphoma - Relapse&#x2F;refractory</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Antifolate analog - inhibits DNA&#x2F;RNA by inhibiting dihydrofolate reductase
Competes for DHFR-folate binding site</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2 12-18 hr
Substrate BCRP&#x2F;ABCG2
Dose adjust for significant renal dysfxn or grade 3+ hepatotoxicity
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2019-Jan </span> <span class="currentMarketDate">Current Market Date: 2019-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047981.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02481820</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97230" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Trifluridine-tipiracil"></div>
<span class="generic">Trifluridine-tipiracil</span> <span class="brand">LONSURF</span>

<span class="class">Antimetabolite</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">met colorectal ca previously treated
met gastric or GE junction ca previously treated</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Trifluridine - thymidine-based analogue inhibiting DNA
Tipiracil - thymidine phosphoralase inhibitor preventing breakdown of trifluridine</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2 Trifluridine 2.1hr, tipiracil 2.4 hr
Many dose reduction criteria
Both hepatic and renal dose adj</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2018-Mar </span> <span class="currentMarketDate">Current Market Date: 2018-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058926.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02472104</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96138" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Capecitabine"></div>
<span class="generic">Capecitabine</span> <span class="brand">XELODA</span>

<span class="class">Antimetabolite</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Colorectal (adj&#x2F;met) and breast (advanced) ca</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Prodrug of fluorouracil - activated in the liver and tissues.
Pyrimidine antimetabolite inhibiting thymidylate synthetase</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 0.75 hr
Metabolized to fluorouracil (T1&#x2F;2: 8-20min)
CYP2C9 weak inhibitor
Many interactions which affect drug levels</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1998-Sep </span> <span class="currentMarketDate">Current Market Date: 1998-Sep</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060777.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02238453</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;61873" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Thioguanine"></div>
<span class="generic">Thioguanine</span> <span class="brand">LANVIS</span>

<span class="class">Antimetabolite</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Acute Leukaemia (ALL)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Purine analogue of guanine inhibiting DNA - blocks synthesis and metabolism of purines</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 5-9 hr
No labelled renal adjustment.
May adjust for hepatic toxicity
**thiopurine methyltransferase testing may be required as this affects metabolism</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1974-Dec </span> <span class="currentMarketDate">Current Market Date: 2017-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050561.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00282081</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1812" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Mercaptopurine"></div>
<span class="generic">Mercaptopurine</span> <span class="brand">PURINETHOL</span>

<span class="class">Antimetabolite</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Acute Leukaemia (ALL)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Purine antagonist inhibiting DNA.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 1.3hr
Metabolized by xanthine oxidase (interaction!)
Active metabolites
TPMT testing**
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1954-Dec </span> <span class="currentMarketDate">Current Market Date: 2014-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00025910.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00004723</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;960" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Acalabrutinib"></div>
<span class="generic">Acalabrutinib</span> <span class="brand">CALQUENCE</span>

<span class="class">BTK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Bruton&#39;s Tyrosine Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL - with obin or monotherapy 1st line
CLL relapse
Mantle Cell Lymphoma</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">2nd gen Bruton&#39;s Tyrosine Kinase inhibitor
BTK integral to Bcell receptor cytokine pathway for proliferation, trafficking adhesion.
Inhibition decreases malignant cell growth</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 1hr
Active metabolite: 3.5hr
Absorption affected by food
3A4 metabolism</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2019-Oct </span> <span class="currentMarketDate">Current Market Date: 2019-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054129.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02491788</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98179" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Ibrutinib"></div>
<span class="generic">Ibrutinib</span> <span class="brand">IMBRUVICA</span>

<span class="class">BTK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Bruton&#39;s Tyrosine Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL -with or without 17P deletion 1st line or relapse. May be in combo with chemo
Mantle Cell, maginal zone Lymphoma, wandenstrom&#39;s 
Steroid dependent&#x2F;refractory GVHD
</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">irreversible BTK inhibitor - Decrease malignant B Cell proliferation</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 4-6hr
CYP3A4
Active metabolite
unknown adj for renal
Adjust for Mild hepatic dysfxn</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2014-Nov </span> <span class="currentMarketDate">Current Market Date: 2014-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061285.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02434407</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91874" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Inotuzumab Ozogamicin"></div>
<span class="generic">Inotuzumab Ozogamicin</span> <span class="brand">BESPONSA</span>

<span class="class">CD22 - MAB-drug conjugate</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD22 Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALL CD22+ relapse&#x2F;refractory</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">CD22 MAB drug conjugate with calicheamicin
CD22 is present on B cells in ALL
Ozogamicin causes DNA strand breaks once internalized by the target cell</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 12.3 days
Risk of hepato-occlusive disease
No offical dose adjustments however liver dysfunction must be monitored</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2018-May </span> <span class="currentMarketDate">Current Market Date: 2018-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044248.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02473909</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96383" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Brentuximab vedotin"></div>
<span class="generic">Brentuximab vedotin</span> <span class="brand">ADCETRIS</span>

<span class="class">CD30 - MAB-drug conjugate</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD30 Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Hodgkin Lymphoma, relapse single agent or with chemo
Post auto transplant consolidation
Post transplant relapse</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">CD 30 MAB drug conjugate with microtubule agent monomethylauristatine E (MMAE)
MMAE is internalized and arrests cell cycle
CD 30 is present on hodgkin&#39;s cells</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 4-6 d
MMAE - chemo 3-4d
MMAE - CYP3A4 Sub
Dose adjust considerations for renal and hepatic dysfx
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2013-Feb </span> <span class="currentMarketDate">Current Market Date: 2021-Jun</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061748.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02401347</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88626" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Gemtuzumab Ozogamicin"></div>
<span class="generic">Gemtuzumab Ozogamicin</span> <span class="brand">MYLOTARG</span>

<span class="class">CD33 - MAB-drug conjugate</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD33 Myeloid Cells</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CD 33+ AML (except APL) in combination with chemotherapy 1st line</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">CD 33 MAB conjugate with calicheamicin.
After internalization calicheamicin  induces DNA strand breaks and cell arrest</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 62-90 hrs
No dose adjustment for renal&#x2F;hepatic dysfxn
may cause hepatotoxicity requiring held dose</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Mar </span> <span class="currentMarketDate">Current Market Date: 2020-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054128.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02494388</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98440" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Polatuzumab vedotin"></div>
<span class="generic">Polatuzumab vedotin</span> <span class="brand">POLIVY</span>

<span class="class">CD79b - MAB-drug conjugate</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD79b Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">DLBCL in combination with bendamustine and rituximab and not eligible to transplant and have at least 1 prior therapy</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">CD 79b present on B cell surface (such as DLBCL). CD 79b MAB conjugate with MMAE. Once internalized MMAE disrupts tubule network causing cell cycle arrest</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: MMAE 4- 12 days
MMAE CYP3A4 Sub
Dose adjust consideration in renal and hepatic dysfxn</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Nov </span> <span class="currentMarketDate">Current Market Date: 2020-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060834.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02499614</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98934" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Palbociclib"></div>
<span class="generic">Palbociclib</span> <span class="brand">IBRANCE</span>

<span class="class">CDK 4&#x2F;6 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Cyclin-dependent Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 29h +- 5 hr
3A4 sub
dose reduced in severe hepatic dysfxn
Multiple dose adjustments for toxicities (hematologic&#x2F;pulmonary)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Sep </span> <span class="currentMarketDate">Current Market Date: 2020-Sep</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054832.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02493535</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98354" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Abemaciclib"></div>
<span class="generic">Abemaciclib</span> <span class="brand">VERZENIO</span>

<span class="class">CDK 4&#x2F;6 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Cyclin-dependent Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18hr
3A4 sub
dose adjust in severe hepatic dysfxn
mulitple dose adjustment for toxicities (heme&#x2F;lung&#x2F;nonheme)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2019-Jul </span> <span class="currentMarketDate">Current Market Date: 2019-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061550.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02487098</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97723" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Ribociclib"></div>
<span class="generic">Ribociclib</span> <span class="brand">KISQALI</span>

<span class="class">CDK 4&#x2F;6 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Cyclin-dependent Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 30-55 hr
3A4 sub
both renal and hepatic dose adj
Multiple dose adjustment for toxicities (heme&#x2F;lung&#x2F;skin&#x2F;other non heme)
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2018-Apr </span> <span class="currentMarketDate">Current Market Date: 2018-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059361.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02473569</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96295" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Cetuximab"></div>
<span class="generic">Cetuximab</span> <span class="brand">ERBITUX</span>

<span class="class">EGFR Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">met Colorectal ca (RAS wild) with or without chemotherapy.
Squamous cell ca HN with radiation with or without chemo</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB to epidermal growth factor receptor which blocks activation of receptor kinases inhibiting cell growth. EGFR activates RAS downstream. RAS mutations result in resistance.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 112 hrs
No dose adj for renal&#x2F;hepatic however for toxicities (dematologic, infusion reactions, pulmonary tox)
** infusion reactions</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2008-Oct </span> <span class="currentMarketDate">Current Market Date: 2010-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043071.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02271249</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75672" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Panitumumab"></div>
<span class="generic">Panitumumab</span> <span class="brand">VECTIBIX</span>

<span class="class">EGFR Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">met Colorectal ca (RAS wild) with or without chemotherapy.</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB to epidermal growth factor receptor which blocks activation of receptor kinases inhibiting cell growth. EGFR activates RAS downstream. RAS mutations result in resistance.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 7.5 days
Dose adjustments for toxicities but not renal&#x2F;hepatic dysfxn</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2008-May </span> <span class="currentMarketDate">Current Market Date: 2008-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00038772.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02308487</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;79412" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Gilteritinib"></div>
<span class="generic">Gilteritinib</span> <span class="brand">XOSPATA</span>

<span class="class">FLT3 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">FMS Like Tyrosine Kinase 3</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">AML FLT3 +, Refractory or Relapsed</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibits FMS-like tyrosine kinase mutations (FLT3).
Mutated FLT3 signals cell proliferation in leukemic cells that express it.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 113 hrs
Onset within 24 hrs
CYP 3A4
Dose adjustments not studied in renal&#x2F;hepatic dysfxn
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Feb </span> <span class="currentMarketDate">Current Market Date: 2020-Feb</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054411.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02495058</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98500" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Midostaurin"></div>
<span class="generic">Midostaurin</span> <span class="brand">RYDAPT</span>

<span class="class">FLT3 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">FMS Like Tyrosine Kinase 3</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">AML FLT3 +, induction and consolidation</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">FLT3 Tyrosine kinase inhibition (also wild type FLT3, KIT, PDGFR, serine&#x2F;threonine protein kinase) leading to apoptosis of leukemic cells</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 19 hr, longer for active metabolites (up to 482 hr)
CYP 3A4
No adjustments for renal&#x2F;hepatic</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2017-Jul </span> <span class="currentMarketDate">Current Market Date: 2017-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061996.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02466236</span></div>
<div><a href="" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Dinutuximab"></div>
<span class="generic">Dinutuximab</span> <span class="brand">UNITUXIN</span>

<span class="class">GD2</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">glycolipid disialoganglioside (GD2)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">High risk neuroblastoma in pediatric patients with partial response to initial therapy. In combination with GM-CSF&#x2F;IL2&#x2F;CisRetinoicAcid</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB targeting GD2, a cell surface protein in neurons (neuroblastoma). Induces apoptosis (ADCC&#x2F;CDC)</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 10 days
no dose adjustment for renal&#x2F;hepatic dysfxn
**Serious infusion reactions.
Requires opioid infusion.
Severe neuropathy&#x2F;neurotoxicity.</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2019-May </span> <span class="currentMarketDate">Current Market Date: 2019-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00048647.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02483076</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97347" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Sonidegib"></div>
<span class="generic">Sonidegib</span> <span class="brand">ODOMZO</span>

<span class="class">Hedgehog Pathway Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Smoothen (SMO) Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Basal cell ca, locally advanced, not amenable to curative radiation&#x2F;surgery</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Hedghog pathway regulates cell growth and differentiation in embryogenesis. Inactive in adults but is activated in basel cell ca.
Binds to smoothened homologue (SMO) involved in pathway signaling.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 28 days
CYP3A4
No labelled dose reduction for renal&#x2F;hepatic dysfxn though adjusted for CK increases</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Dec </span> <span class="currentMarketDate">Current Market Date: 2020-Dec</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056602.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02500337</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;99003" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Vismodegib"></div>
<span class="generic">Vismodegib</span> <span class="brand">ERIVEDGE</span>

<span class="class">Hedgehog Pathway Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Smoothen (SMO) Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Basal cell ca, locally advanced, not amenable to curative radiation&#x2F;surgery</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Hedghog pathway regulates cell growth and differentiation in embryogenesis. Inactive in adults but is activated in basel cell ca.
Binds to smoothened homologue (SMO) involved in pathway signaling.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 4d
not significantly metabolized by CYP
No dose adjustments listed but may need to be held for toxicities (cutaneous)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2013-Aug </span> <span class="currentMarketDate">Current Market Date: 2013-Aug</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056365.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02409267</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89398" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Trastuzumab"></div>
<span class="generic">Trastuzumab</span> <span class="brand">HERCEPTIN</span>

<span class="class">HER2 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Human Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, HER2 positive, (neo)adjuvant with chemo or metastatic</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">HER2 protein is overexpressed in some breast cancers. MAB - targeting of HER2 inducing ADCC</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">No dose adjustments for hepatic or renal dysfxn
May need to be held for LVEF decreases</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2018-Oct </span> <span class="currentMarketDate">Current Market Date: 2018-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056300.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02480697</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97124" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Pertuzumab"></div>
<span class="generic">Pertuzumab</span> <span class="brand">PERJETA</span>

<span class="class">HER2 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Human Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, HER2 positive, (neo)adjuvant with chemo or metastatic</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Binds to HER2 at seperate site from trastuzumab. Used in combination for more compete inhibition of HER 2 in Breast Ca overexpressing HER2</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18d
No dose adjustment for renal or hepatic dysfxn
held if (along with tras) for LVEF decreases</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2013-May </span> <span class="currentMarketDate">Current Market Date: 2013-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060125.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02405016</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88984" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Lapatinib"></div>
<span class="generic">Lapatinib</span> <span class="brand">TYKERB</span>

<span class="class">HER2 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Human Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, met, HER2+ post chemo, in combo with capecitabine
Approved on surrogate endpint (time to progression)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">TKI (EGFR and HER2) blocking cell signaling. May overcome resistance to endocrine therapy in HER2 + hormone receptor pos Breast ca</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 24 hr
CYP 3A4&#x2F;5
Dose adjust in significant hepatic toxicity, cardiac, derm, GI, pulmonary</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2009-Jun </span> <span class="currentMarketDate">Current Market Date: 2016-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00048842.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02326442</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;81179" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Darolutamide"></div>
<span class="generic">Darolutamide</span> <span class="brand">NUBEQA</span>

<span class="class">Hormonal Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Prostate cancer, non metastatic castrate resistant</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Androgen receptor inhibitor resulting in decreased prostate tumor proliferation, and apoptosis</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 20 hrs
CYP 3A4
dose reduced in renal and hepatic dysfxn as well as toxicities (grade 3 general)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Mar </span> <span class="currentMarketDate">Current Market Date: 2020-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062165.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02496348</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98622" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Siltuximab"></div>
<span class="generic">Siltuximab</span> <span class="brand">SYLVANT</span>

<span class="class">IL6 inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">IL6</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Multicentric Castleman’s Disease</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Chimeric antibody to IL2 preventing its binding.
Overproduction of IL6 leads to manifestations of multicentric Castlemans disease. (systemic lymphadenopathy, cytopenias, inflammation, organ dysfunction)</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 21days
Dose adjustments not studies</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2015-Mar </span> <span class="currentMarketDate">Current Market Date: 2021-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059834.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02435128</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91940" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Niraparib"></div>
<span class="generic">Niraparib</span> <span class="brand">ZEJULA</span>

<span class="class">PARP Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Poly ADP-ribose polymerase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Advanced ovarian epithelial ca maint post platinum therapy, 1st line or after relapse and are in complete or partial response</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">inhibits Poly ADP-ribose (PARP-1, PARP-2) which normally detects DNA damage and repair resulting in apoptosis</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 36 hr
Dose adjusted for hepatic dysfxn and various toxicities (cytopenia, GI)
*Risk of MDS&#x2F;AML</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Jan </span> <span class="currentMarketDate">Current Market Date: 2020-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058166.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02489783</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97986" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Olaparib"></div>
<span class="generic">Olaparib</span> <span class="brand">LYNPARZA</span>

<span class="class">PARP Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Poly ADP-ribose polymerase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, HER2 -ve, BRCA germline mutation positive, past treament.
Ovarian epithelial BRCA mutated, in response post platinum therapy
Ovarian epithelial platinum sensitive disease in repsonse - maintenance</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">inhibits Poly ADP-ribose (PARP-1, PARP-2, PARP-3) which normally detects DNA damage and repair resulting in apoptosis
Acts on BRCA 1&#x2F;2 deficient tumors causing DNA breaks that are unable to be repaired</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 14.9 ± 8.2 hours (tabs)
CYP3A4
Dose adjusted in renal dysfxn, and other toxicity (cytopenia, GI, pneumonitis)
*Risk of MDS&#x2F;AML</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2018-May </span> <span class="currentMarketDate">Current Market Date: 2018-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061411.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02475200</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96554" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Ipilimumab"></div>
<span class="generic">Ipilimumab</span> <span class="brand">YERVOY</span>

<span class="class">CTLA-4 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Cytotoxic T Lymphocyte Associated Antigen</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Met melanoma, met renal ca</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">IgG MAB that binds cytotoxic T-Lymphocyte associated antigen 4 (CTLA-4).
CTLA-4 down regulates T cells and by blocking it T cells are able to be activated against tumor cells (renal ca &#x2F;melanoma)
Used in combination with nivolumab to synergy</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 15.4 days
Unique immune mediated toxicity profile. Dose delays for various toxicities (hepatic, renal, GI, cutaneous, thyroid etc)
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2012-Mar </span> <span class="currentMarketDate">Current Market Date: 2012-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060643.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02379384</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86525" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Cemiplimab"></div>
<span class="generic">Cemiplimab</span> <span class="brand">LIBTAYO</span>

<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Met or locally advanced squamous cell ca ineligibile for surgery or radiation</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">IgG MAB that binds to PD-1 blocking PD-L1, PD-L2 binding
Results in T cell activation and tumor detection.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 20 days
No dose adjustments
Immune mediated side effects (Hepatic, GI, cutaneous, pulmonary etc)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2019-May </span> <span class="currentMarketDate">Current Market Date: 2019-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058044.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02487152</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97727" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Avelumab"></div>
<span class="generic">Avelumab</span> <span class="brand">BAVENCIO</span>

<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-L1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Met or locally advanced urothelial ca post platinum
Met merkel cell (skin cancer)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB restores T cell function by binding to PD-L1 preventing interaction with PD-1 (checkpoint)</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 6.1 d
Immune mediated dose adjustment&#x2F;hold</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2017-Dec </span> <span class="currentMarketDate">Current Market Date: 2017-Dec</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059619.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02469723</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95856" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Durvalumab"></div>
<span class="generic">Durvalumab</span> <span class="brand">IMFINZI</span>

<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-L1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Met or locally advanced urothelial ca post platinum
locally advance NSCLC (stage III) with response post radiation
Extensive stage small cell lung ca with chemo (etop&#x2F;platinum)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB - PD-L1 inhibition</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2017-Nov </span> <span class="currentMarketDate">Current Market Date: 2017-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060587.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02468816</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95736" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Pembrolizumab"></div>
<span class="generic">Pembrolizumab</span> <span class="brand">KEYTRUDA</span>

<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Melanoma, NSCLC, Hodgkin lymphoma, Primary mediastinal B cell, Urothelial, Renal Cell,  Colorectal MSI-H, endometrial, H&amp;N Squamous, Esophageal</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB - PD-1 inhibition</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 22d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2017-Jul </span> <span class="currentMarketDate">Current Market Date: 2017-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062141.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02456869</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94388" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Atezolizumab"></div>
<span class="generic">Atezolizumab</span> <span class="brand">TECENTRIQ</span>

<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-L1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Extensive stage small cell lung ca, NSCLC, hepatocellular, locally advanced or met Breast ca, advanced urothelial ca</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB - PD-L1 inhibition</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 27d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2017-May </span> <span class="currentMarketDate">Current Market Date: 2017-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061767.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02462990</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95089" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Nivolumab"></div>
<span class="generic">Nivolumab</span> <span class="brand">OPDIVO</span>

<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">advanced or adj melanoma, met NSCLC, advanced mesothelioma, met Renal cell, squamous HN, classic Hodgkin, Hepatocellular, MSI-H met colorectal, adj GEJ</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB - PD-1 inhibition</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 25 d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2015-Oct </span> <span class="currentMarketDate">Current Market Date: 2015-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062198.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02446626</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93204" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Alpelisib"></div>
<span class="generic">Alpelisib</span> <span class="brand">PIQRAY</span>

<span class="class">PI3 Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Phosphatidylinositol 3 -kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, with fulvestrant, HR+, HER2-ve, PI3CA mutated advanced disease</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor of PI3 kinase which decreases cell signaling</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 8-9h
Dose adjusted for various toxicities (derm, GI, glucose,pancreatitis, lung)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Jun </span> <span class="currentMarketDate">Current Market Date: 2020-Jun</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061787.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02497069</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98692" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Idelalisib"></div>
<span class="generic">Idelalisib</span> <span class="brand">ZYDELIG</span>

<span class="class">PI3 Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Phosphatidylinositol 3 -kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL with ritux in relapse, follicular lymphoma monotherapy in relapse</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibits delta form of PI3Kinase present in lymphoid B cells inhibiting chemotaxis, adhesion and viability.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 8.2hr
3A4 both inhibitor and substrate (strong)
dose adjusted for toxicity (derm, GI, heme, lung,)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2015-Apr </span> <span class="currentMarketDate">Current Market Date: 2015-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057731.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02438798</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92318" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Venetoclax"></div>
<span class="generic">Venetoclax</span> <span class="brand">VENCLEXTA</span>

<span class="class">BCL2 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">B Cell Lymphocyte 2 (BCL2)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL in combo with obinituzumab or rituximab
AML in combination with azacitidine</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">BCL-2 is an anti-apoptotic protein overexpressed in CLL and AML cells. Venetoclax binds directly to BCL-2 restoring apoptotic process.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 26hr
3A4
Dose adjusted in severe hepatic and for toxicities (primarily hematologic)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2016-Oct </span> <span class="currentMarketDate">Current Market Date: 2016-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059710.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02458039</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94509" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Imatinib"></div>
<span class="generic">Imatinib</span> <span class="brand">GLEEVEC</span>

<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CML Ph+, ALL Ph+, MDS (PDGFR gene rearrangment),
Systemic mastocytosis with cKIT mutation, GIST tumor and others</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">In leukemia imatinib is a potent inhibitor of the BCR-ABL fusion protein which is a tyrosine kinase which drives cell devision. Inhibition of the TK inhibits tumor cell growth.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18hr (metabolite 40hr)
CYP 3A4 substrate and inhibitor
*interaction with acetaminophen
Dose reduced in hepatic and renal impairment as well as toxicity</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2005-Apr </span> <span class="currentMarketDate">Current Market Date: 2005-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00053452.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02253275</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;73824" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Lacrotrectinib"></div>
<span class="generic">Lacrotrectinib</span> <span class="brand">VITRAKVI</span>

<span class="class">TRK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Receptor Tyrosine Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060963.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060963.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Nov </span> <span class="currentMarketDate">Current Market Date: 2020-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060963.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02490315</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98037" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Entrectinib"></div>
<span class="generic">Entrectinib</span> <span class="brand">ROZLYTREK</span>

<span class="class">TRK Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Receptor Tyrosine Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059544.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059544.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2020-Mar </span> <span class="currentMarketDate">Current Market Date: 2020-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059544.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02495007</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98496" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Lenvatinib"></div>
<span class="generic">Lenvatinib</span> <span class="brand">LENVIMA</span>

<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059280.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059280.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2019-Oct </span> <span class="currentMarketDate">Current Market Date: 2019-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059280.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02484129</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97445" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Dacometinib"></div>
<span class="generic">Dacometinib</span> <span class="brand">VIZIMPRO</span>

<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">EGFR&#x2F;HER1 HER2 HER4</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050253.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050253.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2019-Apr </span> <span class="currentMarketDate">Current Market Date: 2019-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050253.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02486024</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97625" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Ramucirumab"></div>
<span class="generic">Ramucirumab</span> <span class="brand">Cyramza</span>

<span class="class">VEGF Inhibitor MAB</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">VEGF Receptor 2</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060742.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060742.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2015-Sep </span> <span class="currentMarketDate">Current Market Date: 2015-Sep</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060742.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02443805</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92855" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Bevacizumab"></div>
<span class="generic">Bevacizumab</span> <span class="brand">AVASTIN</span>

<span class="class">VEGF Inhibitor MAB</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">VEGF</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059621.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059621.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2005-Nov </span> <span class="currentMarketDate">Current Market Date: 2005-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059621.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02270994</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75642" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Cyclophosphamide"></div>
<span class="generic">Cyclophosphamide</span> <span class="brand">PROCYTOX</span>

<span class="class">Alkylating Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">multiple</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Alkylation and cross-linking DNA strands</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 3-12 hr
2B6 Major
2C9, 3A4, 2A6 2C19 minor
Adjust in significant renal dysfxn</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2000-Sep </span> <span class="currentMarketDate">Current Market Date: 2003-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00017604.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02241795</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;65460" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Temozolomide"></div>
<span class="generic">Temozolomide</span> <span class="brand">TEMODAL</span>

<span class="class">Alkylating Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00039947.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00039947.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1999-Nov </span> <span class="currentMarketDate">Current Market Date: 2012-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00039947.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02241093</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;64696" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Hydroxyurea"></div>
<span class="generic">Hydroxyurea</span> <span class="brand">HYDREA</span>

<span class="class">Alkylating Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054980.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054980.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1979-Dec </span> <span class="currentMarketDate">Current Market Date: 2004-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054980.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00465283</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;3453" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Lomustine"></div>
<span class="generic">Lomustine</span> <span class="brand">CEENU</span>

<span class="class">Alkylating Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00033792.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00033792.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1976-Dec </span> <span class="currentMarketDate">Current Market Date: 2009-Dec</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00033792.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00360422</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;2530" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Procarbazine"></div>
<span class="generic">Procarbazine</span> <span class="brand">MATULANE</span>

<span class="class">Alkylating Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040636.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040636.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1970-Dec </span> <span class="currentMarketDate">Current Market Date: 2018-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040636.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00012750</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;938" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Melphalan"></div>
<span class="generic">Melphalan</span> <span class="brand">ALKERAN</span>

<span class="class">Alkylating Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050468.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050468.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1964-Dec </span> <span class="currentMarketDate">Current Market Date: 2017-Feb</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050468.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00004715</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1195" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Chorambucil"></div>
<span class="generic">Chorambucil</span> <span class="brand">LEUKERAN</span>

<span class="class">Alkylating Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052423.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052423.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1957-Dec </span> <span class="currentMarketDate">Current Market Date: 2017-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052423.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00004626</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1193" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Exemestane"></div>
<span class="generic">Exemestane</span> <span class="brand">AROMASIN</span>

<span class="class">Aromatase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Aromatase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044156.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044156.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2000-Aug </span> <span class="currentMarketDate">Current Market Date: 2004-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044156.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02242705</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;66502" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Letrozole"></div>
<span class="generic">Letrozole</span> <span class="brand">FEMARA</span>

<span class="class">Aromatase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Aromatase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040278.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040278.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1997-Aug </span> <span class="currentMarketDate">Current Market Date: 1997-Sep</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040278.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02231384</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;50695" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Anastrazole"></div>
<span class="generic">Anastrazole</span> <span class="brand">ARIMIDEX</span>

<span class="class">Aromatase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Aromatase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062049.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062049.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1996-Aug </span> <span class="currentMarketDate">Current Market Date: 2002-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062049.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02224135</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;43395" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Ponatininb"></div>
<span class="generic">Ponatininb</span> <span class="brand">ICLUSIG</span>

<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052729.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052729.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2015-Aug </span> <span class="currentMarketDate">Current Market Date: 2015-Aug</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052729.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02437333</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92168" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Bosutinib"></div>
<span class="generic">Bosutinib</span> <span class="brand">BOSULIF</span>

<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052636.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052636.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2014-Apr </span> <span class="currentMarketDate">Current Market Date: 2014-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052636.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02419149</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90368" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Nilotinib"></div>
<span class="generic">Nilotinib</span> <span class="brand">TASIGNA</span>

<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058886.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058886.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2008-Sep </span> <span class="currentMarketDate">Current Market Date: 2008-Sep</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058886.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02315874</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;80138" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Dasatinib"></div>
<span class="generic">Dasatinib</span> <span class="brand">SPRYCEL</span>

<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057843.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057843.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2007-Apr </span> <span class="currentMarketDate">Current Market Date: 2007-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057843.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02293129</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;77850" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Dabrafenib"></div>
<span class="generic">Dabrafenib</span> <span class="brand">TAFINLAR</span>

<span class="class">BRAF Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BRAF</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060490.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060490.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2013-Aug </span> <span class="currentMarketDate">Current Market Date: 2016-Sep</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060490.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02409607</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89429" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Vemurafenib"></div>
<span class="generic">Vemurafenib</span> <span class="brand">ZELBORAF</span>

<span class="class">BRAF Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BRAF</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054278.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054278.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2012-Mar </span> <span class="currentMarketDate">Current Market Date: 2012-Mar</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054278.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02380242</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86606" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Osimertinib"></div>
<span class="generic">Osimertinib</span> <span class="brand">TAGRISSO</span>

<span class="class">EGFR Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059644.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059644.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2016-Jul </span> <span class="currentMarketDate">Current Market Date: 2016-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059644.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02456214</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94310" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Afatinib"></div>
<span class="generic">Afatinib</span> <span class="brand">GIOTRIF</span>

<span class="class">EGFR Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00051644.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00051644.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2014-Jan </span> <span class="currentMarketDate">Current Market Date: 2014-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00051644.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02415666</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90026" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Erlotinib"></div>
<span class="generic">Erlotinib</span> <span class="brand">TARCEVA</span>

<span class="class">EGFR Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047154.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047154.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2007-Jan </span> <span class="currentMarketDate">Current Market Date: 2007-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047154.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02269007</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75441" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Gefitinib"></div>
<span class="generic">Gefitinib</span> <span class="brand">IRESSA</span>

<span class="class">EGFR Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">EGFR</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060650.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060650.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2003-Dec </span> <span class="currentMarketDate">Current Market Date: 2003-Dec</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060650.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02248676</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;73040" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Abiraterone"></div>
<span class="generic">Abiraterone</span> <span class="brand">ZYTIGA</span>

<span class="class">Enzyme inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway - inhibits CYP 17</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059559.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059559.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2016-Sep </span> <span class="currentMarketDate">Current Market Date: 2016-Sep</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059559.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02457113</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94420" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Romidepsin"></div>
<span class="generic">Romidepsin</span> <span class="brand">ISTODAX</span>

<span class="class">HDAC Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Histone Deacetylase (HDAC)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052382.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052382.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2014-Feb </span> <span class="currentMarketDate">Current Market Date: 2014-Feb</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052382.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02414295</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89895" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Apalutamide"></div>
<span class="generic">Apalutamide</span> <span class="brand">ERLEADA</span>

<span class="class">Hormonal Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062050.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062050.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2018-Jul </span> <span class="currentMarketDate">Current Market Date: 2018-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062050.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02478374</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96913" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Enzalutamide"></div>
<span class="generic">Enzalutamide</span> <span class="brand">XTANDI</span>

<span class="class">Hormonal Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057056.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057056.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2013-Jun </span> <span class="currentMarketDate">Current Market Date: 2013-Jun</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057056.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02407329</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89203" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Flutamide"></div>
<span class="generic">Flutamide</span> <span class="brand">EUFLEX</span>

<span class="class">Hormonal Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050081.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050081.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1998-Oct </span> <span class="currentMarketDate">Current Market Date: 2020-May</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050081.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02238560</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;61987" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Nilutamide"></div>
<span class="generic">Nilutamide</span> <span class="brand">ANANDRON</span>

<span class="class">Hormonal Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055916.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055916.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1997-Aug </span> <span class="currentMarketDate">Current Market Date: 2020-Jun</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055916.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02221861</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;43312" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Bicalutamide"></div>
<span class="generic">Bicalutamide</span> <span class="brand">CASODEX</span>

<span class="class">Hormonal Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040132.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040132.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1996-Dec </span> <span class="currentMarketDate">Current Market Date: 2002-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040132.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02184478</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;19647" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Tamoxifen"></div>
<span class="generic">Tamoxifen</span> <span class="brand">TAMOFEN</span>

<span class="class">Hormonal Agent</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Estrogen Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043973.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043973.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1989-Dec </span> <span class="currentMarketDate">Current Market Date: 1989-Dec</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043973.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00812404</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;10664" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Pomalidomide"></div>
<span class="generic">Pomalidomide</span> <span class="brand">POMALYST</span>

<span class="class">Immunomodulator</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">T, NK NKT, Cytokines Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059857.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059857.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2014-Feb </span> <span class="currentMarketDate">Current Market Date: 2014-Feb</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059857.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02419580</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90423" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Thalidomide"></div>
<span class="generic">Thalidomide</span> <span class="brand">THALOMID</span>

<span class="class">Immunomodulator</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060578.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060578.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2010-Nov </span> <span class="currentMarketDate">Current Market Date: 2010-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060578.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02355191</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;84045" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Lenalidomide"></div>
<span class="generic">Lenalidomide</span> <span class="brand">REVLIMID</span>

<span class="class">Immunomodulator</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">T, NK NKT, Cytokines Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052749.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052749.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2008-Feb </span> <span class="currentMarketDate">Current Market Date: 2008-Feb</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052749.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02304899</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;79016" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Ruxolitinib"></div>
<span class="generic">Ruxolitinib</span> <span class="brand">JAKAVI</span>

<span class="class">JAK1&#x2F;2 Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Janus Kinases 1&#x2F;2</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061980.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061980.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2012-Jul </span> <span class="currentMarketDate">Current Market Date: 2012-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061980.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02388006</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;87357" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Cobimetinib"></div>
<span class="generic">Cobimetinib</span> <span class="brand">COTELLIC</span>

<span class="class">MEK1&#x2F;2 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">MEK1&#x2F;2 Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043025.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043025.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2016-Apr </span> <span class="currentMarketDate">Current Market Date: 2016-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043025.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02452340</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93872" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Trametinib"></div>
<span class="generic">Trametinib</span> <span class="brand">MEKINIST</span>

<span class="class">MEK1&#x2F;2 Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">MEK1&#x2F;2 Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060493.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060493.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2013-Aug </span> <span class="currentMarketDate">Current Market Date: 2016-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060493.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02409623</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89431" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Arsenic Trioxide"></div>
<span class="generic">Arsenic Trioxide</span> <span class="brand">TRISENOX</span>

<span class="class">Misc</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058402.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058402.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2013-Sep </span> <span class="currentMarketDate">Current Market Date: 2018-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058402.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02407833</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89255" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Dexamethasone"></div>
<span class="generic">Dexamethasone</span> <span class="brand">DECADRON</span>

<span class="class">Misc</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1994-Dec </span> <span class="currentMarketDate">Current Market Date: 1994-Dec</span>

<div><a href="" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02023865</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;16262" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Prednisone"></div>
<span class="generic">Prednisone</span> <span class="brand"></span>

<span class="class">Misc</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00030893.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00030893.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1982-Dec </span> <span class="currentMarketDate">Current Market Date: 1982-Dec</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00030893.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00312770</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;4732" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Mitotane"></div>
<span class="generic">Mitotane</span> <span class="brand">LYSODREN</span>

<span class="class">MIsc</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Adrenocortical carcinoma</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055613.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055613.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1979-Dec </span> <span class="currentMarketDate">Current Market Date: 2021-Feb</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055613.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00463221</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;3348" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Temsirolimus"></div>
<span class="generic">Temsirolimus</span> <span class="brand">TORISEL</span>

<span class="class">mTOR Inhibitor</span> <span class="oral">Parenteral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Mammalian Target of Rapamycin</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00037735.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00037735.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2008-Jan </span> <span class="currentMarketDate">Current Market Date: 2011-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00037735.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02304104</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;78941" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Everolimus"></div>
<span class="generic">Everolimus</span> <span class="brand">AFINITOR</span>

<span class="class">mTOR Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Mammalian Target of Rapamycin</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060902.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060902.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2014-Nov </span> <span class="currentMarketDate">Current Market Date: 2014-Nov</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060902.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02425645</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91028" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Etoposide"></div>
<span class="generic">Etoposide</span> <span class="brand">VEPESID</span>

<span class="class">Topoisomerase II Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054405.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054405.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 1984-Dec </span> <span class="currentMarketDate">Current Market Date: 2020-Jan</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054405.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 00616192</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;5963" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Cabozantinib"></div>
<span class="generic">Cabozantinib</span> <span class="brand">CABOMETYX</span>

<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056366.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056366.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2018-Oct </span> <span class="currentMarketDate">Current Market Date: 2018-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056366.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02480824</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97148" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Regorafenib"></div>
<span class="generic">Regorafenib</span> <span class="brand">STIVARGA</span>

<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055344.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055344.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2013-Apr </span> <span class="currentMarketDate">Current Market Date: 2013-Apr</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055344.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02403390</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88820" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Vandetanib"></div>
<span class="generic">Vandetanib</span> <span class="brand">CAPRELSA</span>

<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055721.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055721.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2012-Feb </span> <span class="currentMarketDate">Current Market Date: 2017-Oct</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055721.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02378582</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86437" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Pazopanib"></div>
<span class="generic">Pazopanib</span> <span class="brand">VOTRIENT</span>

<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055255.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055255.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2010-Aug </span> <span class="currentMarketDate">Current Market Date: 2016-Sep</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055255.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02352303</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;83758" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Sorafenib"></div>
<span class="generic">Sorafenib</span> <span class="brand">NEXAVAR</span>

<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055343.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055343.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2006-Jul </span> <span class="currentMarketDate">Current Market Date: 2006-Jul</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055343.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02284227</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;76977" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Sunitinib"></div>
<span class="generic">Sunitinib</span> <span class="brand">SUTENT</span>

<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052172.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052172.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2006-Jun </span> <span class="currentMarketDate">Current Market Date: 2006-Jun</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052172.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02280795</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;76647" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
<div id="Axitinib"></div>
<span class="generic">Axitinib</span> <span class="brand">INLYTA</span>

<span class="class">VEGF Inhibitor</span> <span class="oral">Oral</span>

<table class="datatbl">
<tbody>
<tr>
<td>Target</td>
<td><span class="target">VEGF Receptor (1,2,3)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054598.PDF#INDICATIONS%20AND%20CLINICAL%20USE" target="_blank">HC Monograph Indications</a></td>
</tr>
<tr>
<td>Mechanism</td>
<td><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054598.PDF#ACTION%20AND%20CLINICAL%20PHARMACOLOGY" target="_blank">HC Monograph Mechanism and Pharmacology</a></td>
</tr>

</tbody>
</table>
<span class="originalMarketDate">Orig Market Date: 2012-Aug </span> <span class="currentMarketDate">Current Market Date: 2012-Aug</span>

<div><a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054598.PDF" target="_blank" class="HCdirlink">HC Monograph</a> <span class="din"> DIN: 02389630</span></div>
<div><a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;87513" target="_blank" class="HCpagelink">HC Page</a></div>
<div><a class="toclink" href="#/TOC">TOC</a></div>
---
